Endosense raises $36M in second round for cardiac arrhythmia device

Funding round completed

Endosense, a devices company aiming to improve the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, announced it closed a $36 million second round. Edmond de Rothschild Investment Partners (EdRIP) led the round, with from Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie. The financing will primarily be used to fund the European commercialisation and a US Premarket Approval clinical study of the Geneva-based company’s force-sensing ablation catheter, the TactiCath.  

TactiCath is positioned to greatly improve the treatment of cardiac arrhythmias, a series of life-threatening disorders that affect millions of patients worldwide according to Olivier Litzka, partner at EdRIP. “Ablation is one of the highest-growth markets in the cardiovascular space. Force measurement during the ablation procedure has become a prime object of interest to improve safety and efficacy for patients.”

As part of the round, Endosense has made several board appointments to reflect its new shareholder mix. Litzka, along with Gimv Executive Vice President Life Sciences Patrick van Beneden and VI Partner Diego Braguglia have become directors.

Eric Le Royer, president and chief executive officer, Endosense said, “We believe this investment speaks to the potential of our force-sensing technology and the tremendous clinical value it is anticipated to provide to physicians and patients.”

TactiCath is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.